Akums Drugs and Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals Limited announced its unaudited Q1 FY26 results on August 8, 2025. Consolidated revenue from operations stood at ₹10,240.32 million, almost flat versus ₹10,191.13 million in Q1 FY25 (about 0.5% growth). Consolidated profit after tax rose to ₹646.85 million from ₹612.08 million, while standalone PAT grew to ₹448.67 million from ₹418.75 million. Consolidated EPS was ₹4.15 and standalone EPS was ₹2.93. The CDMO segment continued to dominate, contributing roughly 80% of revenue, while the API and Trade Generics segments remained in losses. The auditor flagged an emphasis-of-matter note relating to the Income Tax Department's search and seizure operation conducted between January 15-21, 2025, for which no order or demand has been received yet. The Board also re-appointed the internal auditor, reconstituted key committees, and designated two senior management personnel.
A largely flat-to-modestly-positive quarter for shareholders, with single-digit PAT growth and stable revenue. The pending Income Tax investigation remains an unresolved overhang and was specifically called out by auditors, which investors should monitor closely for any future demand or order.